

|         | <u>PCDH8+</u> | <u>PCDH8-</u> |
|---------|---------------|---------------|
| LOH+    | 10            | 7             |
| LOH-    | 17            | 1             |
|         | (p=0.0178)    |               |
| Unmeth  | 8             | 7             |
| Meth    | 0             | 6             |
|         | (p=0.0456)    |               |
| ER+     | 26            | 2             |
| ER-     | 3             | 5             |
|         | (p=0.001)     |               |
| PR+     | 21            | 0             |
| PR-     | 8             | 7             |
|         | (p=0.001)     |               |
| S-phase |               |               |
| >10     | 10            | 7             |
| <10     | 13            | 1             |
|         | (p=0.0454)    |               |

**Table S2. PCDH8 loss correlates with loss of heterozygosity (LOH), promoter methylation, loss of estrogen receptor (ER) expression, loss of progesterone receptor (PR) expression, and increased S-phase tumors.**  
 LOH+ = presence of LOH, LOH- = absence of LOH, Unmeth=unmethylated, Meth=methylated.